Vitamin E: Forms, Evidence, and Safety — A Research Guide

Vitamin E: Forms, Evidence, and Safety — A Research Guide

Last Updated:

Table of Contents

Key safety points

  • Vitamin E can inhibit platelet aggregation and oppose vitamin K-dependent clotting factors, so large doses taken with warfarin or other anticoagulant or antiplatelet medicines can raise bleeding risk; the dose needed is unknown but probably exceeds 400 IU a day [2].
  • Men: in SELECT, 400 IU a day of synthetic vitamin E raised prostate cancer risk in healthy men (HR 1.17, 99% CI 1.004 to 1.36) [7].
  • In a meta-analysis of randomised trials, vitamin E increased the risk of haemorrhagic stroke by 22% and reduced ischaemic stroke by 10% [28].
  • If you are having chemotherapy or radiotherapy, ask your oncologist first; oncologists generally advise against antioxidant supplements during treatment [2, 73].
  • The adult UL is 1,000 mg a day, which is 1,500 IU a day of the natural form or 1,100 IU a day of the synthetic form [2]. Some meta-analyses linked 400 IU a day or more, which is below the UL, to higher mortality, mostly in people with chronic disease [2, 69]. The 2022 USPSTF review found no significant link [76].
  • Vitamin E cream on surgical scars gave no benefit in a small trial, and 33% of patients developed contact dermatitis [68].

1. Overview

Vitamin E is the shared name for eight fat-soluble antioxidant compounds: four tocopherols (alpha, beta, gamma, delta) and four tocotrienols (alpha, beta, gamma, delta) [1, 2]. Of these eight forms, only alpha-tocopherol is recognized to meet human requirements, and the RDA covers alpha-tocopherol alone [1, 2].

The biological preference for alpha-tocopherol is determined by the liver. After absorption from the small intestine, the hepatic alpha-tocopherol transfer protein selectively resecretes alpha-tocopherol into the bloodstream while metabolizing and excreting other vitamin E forms [2, 3]. As a result, blood and cellular concentrations of alpha-tocopherol are substantially higher than those of other forms, and alpha-tocopherol has been the subject of the vast majority of clinical research [2, 4].

Vitamin E functions primarily as a chain-breaking antioxidant that halts the propagation of lipid peroxidation in cell membranes and lipoproteins [1, 2]. It stops the production of reactive oxygen species (ROS) formed when polyunsaturated fatty acids undergo oxidation [2]. Beyond its antioxidant role, vitamin E is involved in immune function, cell signaling, regulation of gene expression, and inhibition of platelet aggregation [1, 2]. Alpha-tocopherol inhibits protein kinase C (involved in smooth muscle cell proliferation), enhances prostacyclin release from endothelial cells (promoting vasodilation and inhibiting platelet aggregation), and supports immune cell function [1, 2].

Frank vitamin E deficiency is rare, and overt symptoms have not been found in healthy people who get little vitamin E from their diets [2]. National surveys find that most Americans' diets provide less than the RDA, but these estimates might be low because cooking fats are often not counted, and the Food and Nutrition Board suggests that mean intakes in healthy adults are probably above the RDA [2].

True deficiency occurs mainly in people with fat-malabsorption disorders (for example Crohn's disease, cystic fibrosis, or an inability to secrete bile), in two rare inherited conditions, abetalipoproteinemia and ataxia with vitamin E deficiency (AVED), and in premature babies of very low birth weight [1, 2]. Deficiency symptoms include peripheral neuropathy, ataxia, skeletal myopathy, retinopathy, and impaired immune response [1, 2].

Despite its essential role, vitamin E supplementation has been one of the most extensively studied and most disappointing interventions in clinical nutrition. Large randomized trials in well-nourished people have not shown that it prevents cardiovascular disease or cancer, and some have found harm: in the SELECT trial, healthy men taking vitamin E had more prostate cancer than men on placebo (HR 1.17, 99% CI 1.004 to 1.36) [7]. In 2022 the US Preventive Services Task Force concluded with moderate certainty that vitamin E gives no net benefit for preventing cardiovascular disease or cancer, and it recommends against vitamin E supplements for that purpose [8].

2. Forms and Bioavailability

Natural vs. Synthetic Alpha-Tocopherol

The distinction between natural and synthetic vitamin E is clinically important because it affects both potency and safety.

Natural vitamin E (RRR-alpha-tocopherol, usually labeled d-alpha-tocopherol) exists in a single stereoisomeric form [2]. Supplements often esterify it as alpha-tocopheryl acetate or succinate to extend shelf life, and the body hydrolyzes and absorbs these esters as efficiently as alpha-tocopherol itself [2].

Synthetic vitamin E (all-rac-alpha-tocopherol, usually labeled dl-alpha-tocopherol) contains equal amounts of eight stereoisomers, and serum and tissues maintain only four of them [2]. A given weight of synthetic alpha-tocopherol is therefore only half as active as the same weight of the natural form [2].

IU to Milligram Conversions

Since January 2020, the FDA requires vitamin E to be labeled in milligrams rather than International Units (IU), though products may include both [2, 9]. The conversion factors differ between natural and synthetic forms:

Conversion Natural (d-alpha) Synthetic (dl-alpha)
1 IU equals 0.67 mg alpha-tocopherol 0.45 mg alpha-tocopherol
1 mg alpha-tocopherol equals 1.49 IU 2.22 IU
15 mg (the RDA) equals 22.4 IU 33.3 IU

These conversions matter when comparing doses: 400 IU of natural vitamin E provides 268 mg of alpha-tocopherol, while 400 IU of synthetic vitamin E provides 180 mg [2].

Identifying Natural vs. Synthetic on Labels

Natural vitamin E is usually labeled with the prefix "d-" (d-alpha-tocopherol) and synthetic vitamin E with "dl-" (dl-alpha-tocopherol) [2].

Mixed Tocopherols

Most vitamin E in American diets is gamma-tocopherol from soybean, canola, corn, and other vegetable oils [2, 4]. Supplements typically provide only alpha-tocopherol, although mixed products with other tocopherols and tocotrienols are available [2].

The evidence for gamma-tocopherol is mixed. Animal studies by one group found that gamma- and delta-tocopherols, and a natural mixture of tocopherols, prevented cancer while alpha-tocopherol did not [10]. In a cross-sectional NHANES analysis of 5,768 adults, higher blood gamma-tocopherol was linked to shorter telomeres, a marker of biological aging, while alpha-tocopherol was not [11].

Tocotrienols

Tocotrienols are the four other natural forms of vitamin E, and blood levels of them are lower than those of alpha-tocopherol [2]. In a small 6-week trial, a vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with raised cholesterol [12].

Water-Soluble Forms

People with fat-malabsorption disorders such as Crohn's disease or cystic fibrosis sometimes need a water-soluble form of vitamin E, tocopheryl polyethylene glycol-1000 succinate (TPGS) [1, 2]. Some people with abetalipoproteinemia need very large doses (approximately 100 mg/kg, or 5 to 10 g/day) to prevent neurological damage [1, 2].

3. Evidence for Health Benefits

Alzheimer's Disease and Cognitive Decline

High-dose vitamin E has slowed functional decline in some trials in people with Alzheimer's disease, but it has not prevented cognitive decline or dementia in healthy or mildly impaired people.

Mild to moderate Alzheimer's disease: In the TEAM-AD trial at 14 Veterans Affairs centers, 613 patients with mild to moderate Alzheimer's disease who were taking an acetylcholinesterase inhibitor received 2,000 IU a day of alpha-tocopherol, memantine, both, or placebo [14]. Daily-living scores declined 3.15 units less with alpha-tocopherol than with placebo, a delay of about 6.2 months over the follow-up, and caregiver time rose least in that group; memantine alone or with alpha-tocopherol gave no significant benefit (Dysken, JAMA 2014) [14].

Earlier trials in Alzheimer's: In 341 patients with moderately severe Alzheimer's disease, 2,000 IU a day of alpha-tocopherol delayed the time to death, institutionalization, loss of daily activities or severe dementia, but only after adjusting for a baseline imbalance in cognitive scores (Sano, N Engl J Med 1997) [15]. More people taking vitamin E in that trial had falls [2, 20].

Mild cognitive impairment: In 769 people with amnestic mild cognitive impairment, 2,000 IU of vitamin E daily for three years did not lower progression to Alzheimer's disease (HR 1.02, 95% CI 0.74 to 1.41) (Petersen, N Engl J Med 2005) [16].

Healthy older men, no benefit: In PREADViSE, a dementia study within SELECT that enrolled 7,540 men aged at least 60 years, neither vitamin E nor selenium prevented dementia (vitamin E HR 0.88, 95% CI 0.64 to 1.20) (Kryscio, JAMA Neurol 2017) [17].

Healthy older women, no benefit: In 6,377 women aged 65 or older in the Women's Health Study, 600 IU of vitamin E on alternate days gave no cognitive benefit after 9.6 years of treatment (Kang, Arch Intern Med 2006) [18].

Observational data: In 2,889 community residents aged 65 to 102, the highest intake of vitamin E from foods or supplements was linked to a 36% slower rate of cognitive decline over about 3 years than the lowest intake (Morris, Arch Neurol 2002) [19].

Synthesis: A Cochrane review found no evidence that vitamin E prevents or treats Alzheimer's disease or mild cognitive impairment [20]. The later TEAM-AD trial found slower functional decline in mild to moderate Alzheimer's disease [14], but trials in healthy or mildly impaired people show no benefit [16, 17, 18].

Cardiovascular Disease

Vitamin E was once considered promising for cardiovascular disease (CVD) prevention based on strong observational evidence, but randomized clinical trials have consistently failed to demonstrate benefit, and some suggest harm.

Observational studies (positive): Among 87,245 female nurses, those in the top fifth of vitamin E intake had a relative risk of major coronary disease of 0.66 (95% CI 0.50 to 0.87), and most of the difference came from supplements (Stampfer, N Engl J Med 1993) [21]. Among 5,133 Finnish men and women followed for 14 years, higher dietary vitamin E intakes were associated with decreased coronary heart disease mortality (Knekt, Am J Epidemiol 1994) [22].

HOPE and HOPE-TOO trials (no benefit, possible harm): The Heart Outcomes Prevention Evaluation study followed almost 10,000 patients at high cardiovascular risk for 4.5 years. Participants taking 400 IU/day of natural vitamin E (268 mg) experienced no fewer cardiovascular events than placebo [23]. In the HOPE-TOO extension, with a median follow-up of 7.0 years, vitamin E did not prevent major cardiovascular events, but it raised the risk of heart failure (RR 1.13, 95% CI 1.01 to 1.26) and of hospitalization for heart failure (RR 1.21, 95% CI 1.00 to 1.47) (Lonn, JAMA 2005) [24].

Women's Angiographic Vitamin and Estrogen Study (harm): In 423 postmenopausal women with coronary stenosis, 400 IU of vitamin E plus 500 mg of vitamin C twice daily gave no cardiovascular benefit, and more women died in the vitamin group (16 vs 6 deaths; HR 2.8, 95% CI 1.1 to 7.2) (Waters, JAMA 2002) [25].

Women's Health Study (mixed): Among nearly 40,000 healthy women aged at least 45 years who took 600 IU of natural-source vitamin E on alternate days or placebo for an average of 10.1 years, vitamin E did not reduce major cardiovascular events, but cardiovascular deaths fell by 24% (RR 0.76, 95% CI 0.59 to 0.98) (Lee, JAMA 2005) [26]. In women aged at least 65 years, the trial reported a 26% decrease in nonfatal heart attack and a 49% decrease in cardiovascular death [2].

Physicians' Health Study II (no benefit): In 14,641 US male physicians aged 50 or older, 400 IU of vitamin E every other day for a mean of 8 years did not lower major cardiovascular events (HR 1.01, 95% CI 0.90 to 1.13), but it raised the risk of hemorrhagic stroke (HR 1.74, 95% CI 1.04 to 2.91) (Sesso, JAMA 2008) [27].

Stroke risk: A meta-analysis of nine randomized trials found that vitamin E lowered ischemic stroke risk by 10% but raised hemorrhagic stroke risk by 22%, and its authors warned against widespread, indiscriminate use (Schurks, BMJ 2010) [28].

Interaction with cholesterol drugs: In patients with coronary disease and low HDL treated with simvastatin plus niacin, a combination of antioxidants (vitamins E and C, beta-carotene and selenium) blunted the rise in HDL cholesterol, especially the HDL2 fraction (Brown, N Engl J Med 2001; Cheung, Arterioscler Thromb Vasc Biol 2001) [29, 30].

USPSTF conclusion: In 2022 the US Preventive Services Task Force found, with moderate certainty, that vitamin E gives no net benefit in preventing cardiovascular disease, and it recommends against vitamin E supplements for that purpose (USPSTF, JAMA 2022) [8]. Its evidence review found that vitamin E was not significantly associated with all-cause mortality (OR 1.02, 95% CI 0.97 to 1.07) or cardiovascular disease events (OR 0.96, 95% CI 0.90 to 1.04) [76].

Cancer

Despite initial promise from observational studies, clinical trials have not demonstrated that vitamin E supplementation prevents cancer. For prostate cancer, the evidence points toward increased risk.

Prostate cancer, SELECT trial: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) randomized 35,533 relatively healthy men to 400 IU a day of synthetic vitamin E (all-rac-alpha-tocopheryl acetate), 200 mcg a day of selenium, both, or placebo [7]. With extended follow-up, the vitamin E group had more prostate cancer than placebo (HR 1.17, 99% CI 1.004 to 1.36), an absolute increase of 1.6 cases per 1,000 person-years (Klein, JAMA 2011) [7]. A later analysis split the men by toenail selenium: among those with lower selenium status, vitamin E raised total prostate cancer by 63% and high-grade disease by 111%, with no effect in men with higher status, while selenium supplements raised high-grade disease by 91% in men whose status was already high. The authors concluded that men should avoid selenium or vitamin E supplements at doses above recommended dietary intakes (Kristal, JNCI 2014) [31].

ATBC study in smokers: In 29,133 male smokers aged 50 to 69 years, 50 mg a day of alpha-tocopherol for five to eight years did not reduce lung cancer (ATBC, N Engl J Med 1994) [32], but prostate cancer incidence fell by 32% (Heinonen, JNCI 1998) [33]. These results helped prompt the larger SELECT trial, which later found harm with 400 IU of synthetic vitamin E [2].

HOPE-TOO (no benefit): No significant differences in new cancer diagnoses or cancer deaths were found between vitamin E (400 IU/day natural) and placebo groups after 7 years (Lonn, JAMA 2005) [24].

Women's Health Study (no benefit): Among nearly 40,000 healthy women, 600 IU natural vitamin E every other day for 10 years did not reduce the risk of any form of cancer (Lee, JAMA 2005) [26].

Colon cancer, mixed: In 35,215 Iowa women aged 55 to 69 years, the highest fifth of total vitamin E intake had a relative risk of colon cancer of 0.32 (95% CI 0.19 to 0.54) compared with the lowest fifth, and the association was strongest in younger women (Bostick, Cancer Res 1993) [34]. However, prospective cohort studies of 87,998 women (Nurses' Health Study) and 47,344 men (Health Professionals Follow-up Study) failed to replicate this finding (Wu, Cancer Epidemiol Biomarkers Prev 2002) [35].

Bladder cancer: An epidemiological study of almost one million adults by the American Cancer Society found that adults who took supplemental vitamin E for 10 years or longer had a reduced risk of death from bladder cancer (Jacobs, Am J Epidemiol 2002) [36]. Vitamin C supplementation provided no such protection.

Liver cancer: In two Shanghai cohorts of 132,837 adults, higher dietary vitamin E intake and vitamin E supplement use (HR 0.52, 95% CI 0.30 to 0.90) were associated with lower liver cancer risk (Zhang, JNCI 2012) [37]. Observational findings like this cannot show cause and effect.

USPSTF conclusion: The same 2022 statement found no net benefit of vitamin E in preventing cancer (USPSTF, JAMA 2022) [8].

Eye Diseases

Age-related macular degeneration (AMD): A meta-analysis of prospective cohort studies found that dietary antioxidants, vitamin E included, had little or no effect on preventing early AMD [40]. In a 4-year trial in 1,193 healthy volunteers, 500 IU of vitamin E a day did not prevent early or late AMD [41].

The Age-Related Eye Disease Study (AREDS) gave 3,640 people aged 55 to 80 years with early-to-intermediate AMD, or advanced AMD in one eye, antioxidants (vitamin C 500 mg, vitamin E 400 IU, and beta-carotene 15 mg), zinc 80 mg with copper 2 mg, both, or placebo; antioxidants plus zinc reduced the odds of developing advanced AMD (OR 0.72, 99% CI 0.52 to 0.98) over an average of 6.3 years [43]. AREDS2 later confirmed the value of this and similar formulations [2, 44]. This benefit was from a specific combination formula, not vitamin E alone.

Cataracts: Results are generally negative. In 11,545 US male physicians, vitamin E 400 IU on alternate days, vitamin C 500 mg daily, or both for 8 years left cataract risk unchanged (vitamin E HR 0.99, 95% CI 0.88 to 1.11) (Christen, Arch Ophthalmol 2010) [45]. In the SELECT eye study, synthetic vitamin E at 400 IU a day, with or without selenium, did not lower age-related cataract (HR 1.02, 95% CI 0.84 to 1.25) (Christen, JAMA Ophthalmol 2015) [46]. In ATBC, 50 mg a day of alpha-tocopherol for 5 to 8 years did not change cataract prevalence [42]. Some observational studies link vitamin E supplement use to slower lens opacification, but supplementation trials have not confirmed this [47, 48].

Liver Disease (NAFLD/MASLD)

Liver disease is one of the few areas where trials of high-dose vitamin E have found benefit.

NASH, positive: Two trials gave 800 IU of vitamin E a day for 96 weeks:

  • In 247 adults with nonalcoholic steatohepatitis (NASH) and without diabetes, NASH improved in 43% of those taking vitamin E compared with 19% on placebo; vitamin E also lowered liver enzymes (ALT and AST) and reduced liver fat and inflammation, but it did not improve fibrosis (Sanyal, N Engl J Med 2010) [50].
  • In 173 children and adolescents aged 8 to 17 years with NAFLD, vitamin E did not achieve the main goal of a sustained fall in ALT, but it reduced hepatocellular ballooning, and NASH resolved in 58% of children with NASH taking vitamin E compared with 28% on placebo (Lavine, JAMA 2011) [51].

A later trial, no benefit: In 203 adults (mean age 51) with MASLD, six months of daily vitamin E, 1,000 mg, alone or with DHA, left liver fat and liver enzymes no better than placebo (Alkhouri, Aliment Pharmacol Ther 2024) [52].

Tocotrienols, insufficient evidence: In 100 adults with NAFLD, delta-tocotrienol 300 mg twice daily and alpha-tocopherol 268 mg twice daily for 48 weeks improved liver fat and insulin resistance to a similar degree, with no placebo group (Pervez, Complement Ther Med 2022) [53]. More research is needed.

Important caveat: Before using vitamin E for fatty liver, weigh the prostate cancer signal in SELECT [7] and the heart failure signal in HOPE-TOO [24] with your doctor.

Parkinson's Disease

Oxidative stress may play a part in Parkinson's disease, which made vitamin E a plausible candidate to test.

Pilot study: An early open pilot trial tested high-dose antioxidants in people with Parkinson's disease (Fahn, Ann N Y Acad Sci 1989) [55].

DATATOP trial (no benefit): In the DATATOP trial of 800 people with early Parkinson's disease, tocopherol at 2,000 IU a day, over a mean follow-up of 14 months, gave no benefit on the time until disability required levodopa (Parkinson Study Group, N Engl J Med 1993) [56].

Diabetes and Diabetic Neuropathy

Diabetic neuropathy, small trial, positive: In a 12-week trial in 92 people with diabetic neuropathy, adding vitamin E to usual care (pregabalin and diabetes tablets) reduced pain scores compared with usual care alone (Rajanandh, Pharmacol Rep 2014) [57].

Tocotrienols for neuropathy, no benefit: In 300 patients with diabetic neuropathy, 200 mg of mixed tocotrienols twice daily for a year left overall neuropathic symptoms no better than placebo, and more infections occurred in the tocotrienol group (6.7% vs 0.7%) (Hor, JAMA Neurol 2018) [58].

Cyclic Mastalgia (Breast Pain)

Combination therapy, modest benefit: In 126 premenopausal women with cyclical breast pain, evening primrose oil 1,000 mg twice daily plus vitamin E 400 mg once daily for six months reduced pain severity by a mean of 4.5 points, more than either alone or placebo (Kumari, Cureus 2024) [59].

Higher-dose trial, uncertain: In a US pilot trial in which 41 women finished, daily doses of 1,200 IU vitamin E, 3,000 mg evening primrose oil, or both for six months did not reduce breast pain significantly more than placebo (Pruthi, Altern Med Rev 2010) [60].

Immune Function

Vitamin E is involved in immune function, and deficiency impairs the immune response [2].

Topical Uses

Sunburn prevention: Applied to the skin before UV exposure, vitamins E and C each gave modest protection against sunburn redness, and combinations with melatonin protected better (Dreher, Br J Dermatol 1998) [62]. Taking 400 IU of vitamin E by mouth each day for 6 months gave no meaningful protection against UVB damage in a small trial (Werninghaus, Arch Dermatol 1994) [63].

Wrinkle reduction: In an open study, a gel combining vitamin E with phytonadione, retinol and vitamin C slightly decreased lower-eyelid wrinkles [64]. Controlled clinical studies that define doses and uses of vitamin E in skin care are scarce [67].

Scarring: Vitamin E cream did not improve the appearance of surgical scars, worsened it in some cases, and caused contact dermatitis in 33% of patients (Baumann, Dermatol Surg 1999) [68].

Hair Growth (Tocotrienols)

In a small trial in volunteers with hair loss (21 on tocotrienols, 17 on placebo), hair count rose by 34.5% after 8 months of 100 mg of mixed tocotrienols daily, compared with a 0.1% decrease with placebo; hair weight changed little in either group (Beoy, Trop Life Sci Res 2010) [13].

Recommended Dietary Allowances (RDAs)

The RDA is set in milligrams of alpha-tocopherol: 1 mg of vitamin E equals 1 mg of natural or 2 mg of synthetic alpha-tocopherol [1, 2].

Age Group RDA (mg/day) Natural (IU) Synthetic (IU)
0-6 months* 4 mg 6 IU 9 IU
7-12 months* 5 mg 7 IU 11 IU
1-3 years 6 mg 9 IU 13 IU
4-8 years 7 mg 10 IU 16 IU
9-13 years 11 mg 16 IU 24 IU
14+ years 15 mg 22 IU 33 IU
Lactating women 19 mg 28 IU 42 IU

*Adequate Intake (AI), not RDA, for infants.

Tolerable Upper Intake Levels (ULs)

Vitamin E in food has not been linked to harm, so the ULs concern supplements [1, 2]. The Food and Nutrition Board set them to limit bleeding risk, and they cover all forms of supplemental alpha-tocopherol, including the eight stereoisomers in synthetic vitamin E [2].

Age Group UL (mg/day) Natural (IU) Synthetic (IU)
1-3 years 200 mg 300 IU 220 IU
4-8 years 300 mg 450 IU 330 IU
9-13 years 600 mg 900 IU 660 IU
14-18 years 800 mg 1,200 IU 880 IU
19+ years 1,000 mg 1,500 IU 1,100 IU

Dosing for Specific Conditions

Doses used in trials for medical conditions:

  • NASH/NAFLD: 800 IU a day was the dose in the adult and child trials [50, 51]. Use should be discussed with a healthcare provider given the risks at this dose.
  • Alzheimer's disease: 2,000 IU a day of alpha-tocopherol slowed functional decline in some trials in established Alzheimer's disease. This exceeds the UL and requires physician supervision [14, 15].

Note: Doses above the UL carry more risk and need medical supervision. A meta-analysis of 19 trials found that high-dosage vitamin E (400 IU a day or more) may increase all-cause mortality, with risk rising above 150 IU a day; those trials were often small and in people with chronic disease, so the findings may not apply to healthy adults (Miller, Ann Intern Med 2005) [69].

From the MicroVitamin range

MicroVitamin deliberately leaves out vitamin E. In the SELECT trial, men taking 400 IU a day of synthetic vitamin E had more prostate cancer than men on placebo, and the US Preventive Services Task Force found no net benefit for heart disease or cancer prevention. Most people get enough vitamin E from their diet, and a supplement on top can push levels too high. MicroVitamin. See MicroVitamin

5. Safety and Side Effects

Bleeding Risk

The primary safety concern with vitamin E supplementation is an increased risk of hemorrhage. Vitamin E inhibits platelet aggregation and antagonizes vitamin K-dependent clotting factors [1, 2]. The amount needed for a clinically significant effect is unknown but probably exceeds 400 IU a day, and the UL is set to limit this risk [2]. If you are having surgery, tell your surgeon you take vitamin E.

A meta-analysis of nine randomized trials found that vitamin E increased haemorrhagic stroke by 22% and reduced ischaemic stroke by 10% (Schurks, BMJ 2010) [28]. In the Physicians' Health Study II, 400 IU of vitamin E every other day raised the risk of hemorrhagic stroke (HR 1.74, 95% CI 1.04 to 2.91) (Sesso, JAMA 2008) [27]; most of those physicians also took aspirin, which may point to a bleeding tendency [2]. In the ATBC study in Finnish male smokers, more deaths from hemorrhagic stroke occurred with 50 mg a day of alpha-tocopherol [32].

Prostate Cancer Risk

The SELECT trial provides the strongest evidence: 400 IU a day of synthetic vitamin E raised prostate cancer risk in healthy men (HR 1.17, 99% CI 1.004 to 1.36) (Klein, JAMA 2011) [7]. In men with lower selenium status, high-grade prostate cancer rose by 111% with vitamin E (Kristal, JNCI 2014) [31].

All-Cause Mortality

Two meta-analyses raised concerns about vitamin E and mortality:

  • A meta-analysis of 19 trials found that high-dosage vitamin E (400 IU a day or more) may increase all-cause mortality, with risk rising at doses above 150 IU a day (Miller, Ann Intern Med 2005) [69].
  • A meta-analysis of antioxidant supplement trials found that, in trials at low risk of bias, vitamin E given alone or with other antioxidants increased mortality (RR 1.04, 95% CI 1.01 to 1.07) (Bjelakovic, JAMA 2007) [70].

However, participants in these studies were typically middle-aged or older with chronic diseases, and a review of trials that gave vitamin E to healthy people for primary prevention found no convincing evidence that it increased mortality [2]. The USPSTF evidence review also found no significant link with all-cause mortality [76]. The implications remain debated.

Heart Failure

In HOPE-TOO, vitamin E raised the risk of heart failure (RR 1.13, 95% CI 1.01 to 1.26) and of hospitalization for heart failure (RR 1.21, 95% CI 1.00 to 1.47) (Lonn, JAMA 2005) [24]. Other large studies have not reported this finding [2].

Antioxidant Interference with Cancer Treatment

Oncologists generally advise against antioxidant supplements, including vitamin E, during chemotherapy or radiotherapy because they might reduce treatment effectiveness by protecting cancer cells from oxidative damage [2, 73]. A systematic review of randomized trials has questioned this concern, but more research is needed, so ask your oncologist before taking vitamin E during treatment [2].

Special Populations

Premature infants: Very low birth weight infants (<1,500 g) may be vitamin E deficient. Supplementation may reduce some complications (e.g., retinopathy) but can also increase infection risk [1, 2].

People on low-fat diets: A low-fat diet might supply too little vitamin E unless food choices are made carefully, for example by eating more nuts and seeds [2].

People with rare inherited disorders: Some people with abetalipoproteinemia need 5 to 10 g/day of supplemental vitamin E, and people with AVED need large doses to prevent nerve damage [1, 2].

6. Drug Interactions

Vitamin E supplements interact with several medication classes. People taking these medications should discuss vitamin E use with their healthcare provider [1, 2].

Anticoagulant and Antiplatelet Medications

Vitamin E inhibits platelet aggregation and antagonizes vitamin K-dependent clotting factors. Large doses taken with anticoagulant or antiplatelet medicines such as warfarin can increase bleeding risk, especially with low vitamin K intake; the amount needed for a clinically significant effect is unknown but probably exceeds 400 IU a day [1, 2].

Simvastatin and Niacin

A combination of antioxidants including vitamin E and vitamin C blunted the HDL-raising benefits of simvastatin-niacin therapy, reducing levels of HDL2 (the most cardioprotective component) in patients with coronary artery disease (Brown, N Engl J Med 2001; Cheung, Arterioscler Thromb Vasc Biol 2001) [29, 30].

Chemotherapy and Radiation Therapy

Vitamin E and other antioxidants may reduce the efficacy of chemotherapy and radiotherapy by inhibiting the oxidative damage these treatments rely on to kill cancer cells. Oncologists generally advise against antioxidant supplementation during cancer treatment [2, 73].

Cholesterol-Lowering Agents

The trial evidence concerns the simvastatin-niacin combination above, where vitamin E was given with other antioxidants [29, 30]. If you take prescription medicines, check with your doctor or pharmacist before starting.

7. Dietary Sources

Vitamin E is widely available in the food supply. Nuts, seeds, and vegetable oils are the richest sources of alpha-tocopherol. The RDA of 15 mg/day is achievable through diet for most people making informed food choices [1, 2].

Selected Food Sources of Alpha-Tocopherol

Food Serving Size Alpha-Tocopherol (mg) % DV (15 mg)
Wheat germ oil 1 tablespoon 20.3 135%
Sunflower seeds, dry roasted 1 ounce 7.4 49%
Almonds, dry roasted 1 ounce 6.8 45%
Sunflower oil 1 tablespoon 5.6 37%
Safflower oil 1 tablespoon 4.6 31%
Hazelnuts, dry roasted 1 ounce 4.3 29%
Peanut butter 2 tablespoons 2.9 19%
Peanuts, dry roasted 1 ounce 2.2 15%
Corn oil 1 tablespoon 1.9 13%
Spinach, boiled 1/2 cup 1.9 13%
Broccoli, chopped, boiled 1/2 cup 1.2 8%
Soybean oil 1 tablespoon 1.1 7%
Kiwifruit 1 medium 1.1 7%
Mango, sliced 1/2 cup 0.7 5%
Tomato, raw 1 medium 0.7 5%

Source: NIH ODS, USDA FoodData Central [1, 75].

Practical Notes

  • Most vitamin E in the American diet comes as gamma-tocopherol from soybean, canola, corn, and other vegetable oils, not alpha-tocopherol [2, 4].
  • A single ounce of sunflower seeds or almonds provides roughly half the daily requirement.
  • People on very low-fat diets may need to increase their intake of nuts, seeds, fruits, and vegetables to meet requirements [2].
  • Frank deficiency is rare and is seen mostly in people who cannot absorb fat normally [1, 2].

8. References

[1] Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes: Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academy Press, 2000.

[2] National Institutes of Health, Office of Dietary Supplements. "Vitamin E — Health Professional Fact Sheet." Updated March 26, 2021. https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/

[3] Traber MG. "Vitamin E regulatory mechanisms." Annu Rev Nutr. 2007;27:347-62. https://pubmed.ncbi.nlm.nih.gov/17439363/

[4] Dietrich M, Traber MG, Jacques PF, Cross CE, Hu Y, Block G. "Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? A review." Am J Coll Nutr. 2006;25:292-9. https://pubmed.ncbi.nlm.nih.gov/16943450/

[7] Klein EA, Thompson IM Jr, Tangen CM, et al. "Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)." JAMA. 2011;306:1549-1556. https://pubmed.ncbi.nlm.nih.gov/21990298/

[8] Mangione CM, et al. "Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement." JAMA. 2022. PMID: 35727271. https://pubmed.ncbi.nlm.nih.gov/35727271/

[9] US Food and Drug Administration. "Food Labeling: Revision of the Nutrition and Supplement Facts Labels." 2016.

[10] Yang CS, Suh N, Kong AN. "Does vitamin E prevent or promote cancer?" Cancer Prev Res. 2012;5(5):701-5. PMID: 22490437. https://pubmed.ncbi.nlm.nih.gov/22490437/

[11] Tucker LA. "Alpha- and Gamma-Tocopherol and Telomere Length in 5768 US Men and Women: A NHANES Study." Nutrients. 2017;9(6):601. https://doi.org/10.3390/nu9060601 PMID: 28629117. https://pubmed.ncbi.nlm.nih.gov/28629117/

[12] Mensink RP, van Houwelingen AC, Kromhout D, Hornstra G. "A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations." Am J Clin Nutr. 1999;69:213-9. PMID: 9989682. https://pubmed.ncbi.nlm.nih.gov/9989682/

[13] Beoy LA, Woei WJ, Hay YK. "Effects of tocotrienol supplementation on hair growth in human volunteers." Trop Life Sci Res. 2010;21(2):91-9. PMID: 24575202. https://pubmed.ncbi.nlm.nih.gov/24575202/

[14] Dysken MW, Sano M, Asthana S, et al. "Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial." JAMA. 2014;311(1):33-44. https://pubmed.ncbi.nlm.nih.gov/24381967/

[15] Sano M, Ernesto C, Thomas RG, et al. "A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease." N Engl J Med. 1997;336:1216-22. https://pubmed.ncbi.nlm.nih.gov/9110909/

[16] Petersen RC, Thomas RG, Grundman M, et al. "Vitamin E and donepezil for the treatment of mild cognitive impairment." N Engl J Med. 2005;352:2379-88. https://pubmed.ncbi.nlm.nih.gov/15829527/

[17] Kryscio RJ, Abner EL, Caban-Holt A, et al. "Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE)." JAMA Neurol. 2017;74(5):567-573. PMID: 28319243. https://pubmed.ncbi.nlm.nih.gov/28319243/

[18] Kang JH, Cook N, Manson J, Buring J, Grodstein F. "A randomized trial of vitamin E supplementation and cognitive function in women." Arch Intern Med. 2006;166:2462-8. https://pubmed.ncbi.nlm.nih.gov/17159011/

[19] Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. "Vitamin E and cognitive decline in older persons." Arch Neurol. 2002;59:1125-32. https://pubmed.ncbi.nlm.nih.gov/12117360/

[20] Isaac MGEKN, Quinn R, Tabet N. "Vitamin E for Alzheimer's disease and mild cognitive impairment." Cochrane Database Syst Rev. 2008;(3):CD002854. https://pubmed.ncbi.nlm.nih.gov/18646084/

[21] Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. "Vitamin E consumption and the risk of coronary disease in women." N Engl J Med. 1993;328:1444-9. https://pubmed.ncbi.nlm.nih.gov/8479463/

[22] Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. "Antioxidant vitamin intake and coronary mortality in a longitudinal population study." Am J Epidemiol. 1994;139:1180-9. https://pubmed.ncbi.nlm.nih.gov/8209876/

[23] Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. "Vitamin E supplementation and cardiovascular events in high-risk patients." N Engl J Med. 2000;342:154-60. https://pubmed.ncbi.nlm.nih.gov/10639540/

[24] Lonn E, Bosch J, Yusuf S, et al. "Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial." JAMA. 2005;293:1338-47. https://pubmed.ncbi.nlm.nih.gov/15769967/

[25] Waters DD, Alderman EL, Hsia J, et al. "Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women." JAMA. 2002;288:2432-40. https://pubmed.ncbi.nlm.nih.gov/12435256/

[26] Lee IM, Cook NR, Gaziano JM, et al. "Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study." JAMA. 2005;294:56-65. https://pubmed.ncbi.nlm.nih.gov/15998891/

[27] Sesso HD, Buring JE, Christen WG, et al. "Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial." JAMA. 2008;300:2123-33. https://pubmed.ncbi.nlm.nih.gov/18997197/

[28] Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. "Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials." BMJ. 2010;341:c5702. PMID: 21051774. https://pubmed.ncbi.nlm.nih.gov/21051774/

[29] Brown BG, Zhao XQ, Chait A, et al. "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease." N Engl J Med. 2001;345:1583-92. https://pubmed.ncbi.nlm.nih.gov/11757504/

[30] Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. "Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL." Arterioscler Thromb Vasc Biol. 2001;21:1320-6. https://pubmed.ncbi.nlm.nih.gov/11498460/

[31] Kristal AR, Darke AK, Morris JS, et al. "Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk." J Natl Cancer Inst. 2014;106(3):djt456. PMID: 24563519. https://pubmed.ncbi.nlm.nih.gov/24563519/

[32] Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. "The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers." N Engl J Med. 1994;330:1029-35. https://pubmed.ncbi.nlm.nih.gov/8127329/

[33] Heinonen OP, Albanes D, Virtamo J, et al. "Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial." J Natl Cancer Inst. 1998;90(6):440-6. https://pubmed.ncbi.nlm.nih.gov/9521168/

[34] Bostick RM, Potter JD, McKenzie DR, et al. "Reduced risk of colon cancer with high intakes of vitamin E: the Iowa Women's Health Study." Cancer Res. 1993;15:4230-7. https://pubmed.ncbi.nlm.nih.gov/8364919/

[35] Wu K, Willett WC, Chan JM, et al. "A prospective study on supplemental vitamin E intake and risk of colon cancer in women and men." Cancer Epidemiol Biomarkers Prev. 2002;11:1298-304. https://pubmed.ncbi.nlm.nih.gov/12433706/

[36] Jacobs EJ, Henion AK, Briggs PJ, et al. "Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women." Am J Epidemiol. 2002;156:1002-10. https://pubmed.ncbi.nlm.nih.gov/12446256/

[37] Zhang W, Shu XO, Li H, et al. "Vitamin intake and liver cancer risk: a report from two cohort studies in China." J Natl Cancer Inst. 2012;104(15):1173-81. PMID: 22811438. https://pubmed.ncbi.nlm.nih.gov/22811438/

[40] Chong EWT, Wong TY, Kreis AJ, Simpson JA, Guymer RH. "Dietary antioxidants and primary prevention of age-related macular degeneration: systematic review and meta-analysis." BMJ. 2007;335:755. https://pubmed.ncbi.nlm.nih.gov/17923720/

[41] Taylor HR, Tikellis G, Robman LD, McCarty CA, McNeil JJ. "Vitamin E supplementation and macular degeneration: randomized controlled trial." BMJ. 2002;325:11. https://pubmed.ncbi.nlm.nih.gov/12098721/

[42] Teikari JM, Virtamo J, Rautalahti M, Palmgren J, Liesto K, Heinonen OP. "Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract." Acta Ophthalmol Scand. 1997;75:634-40. https://pubmed.ncbi.nlm.nih.gov/9527321/

[43] Age-Related Eye Disease Study Research Group. "A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8." Arch Ophthalmol. 2001;119:1417-36. https://pubmed.ncbi.nlm.nih.gov/11594942/

[44] The Age-Related Eye Disease Study 2 (AREDS2) Research Group. "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration." JAMA. 2013;309:2005-15. https://pubmed.ncbi.nlm.nih.gov/23644932/

[45] Christen WG, Glynn RJ, Sesso HD, et al. "Age-related cataract in a randomized trial of vitamins E and C in men." Arch Ophthalmol. 2010;128(11):1397-405. PMID: 21060040. https://pubmed.ncbi.nlm.nih.gov/21060040/

[46] Christen WG, Glynn RJ, Gaziano JM, et al. "Age-related cataract in men in the selenium and vitamin E cancer prevention trial eye endpoints study: a randomized clinical trial." JAMA Ophthalmol. 2015. PMID: 25232809. https://pubmed.ncbi.nlm.nih.gov/25232809/

[47] Leske MC, Chylack LT Jr, He Q, et al. "Antioxidant vitamins and nuclear opacities: the longitudinal study of cataract." Ophthalmology. 1998;105:831-6. https://pubmed.ncbi.nlm.nih.gov/9593382/

[48] Jacques PF, Taylor A, Moeller S, et al. "Long-term nutrient intake and 5-year change in nuclear lens opacities." Arch Ophthalmol. 2005;123:517-26. https://pubmed.ncbi.nlm.nih.gov/15824226/

[50] Sanyal AJ, Chalasani N, Kowdley KV, et al. "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis." N Engl J Med. 2010;362:1675-85. PMID: 20427778. https://pubmed.ncbi.nlm.nih.gov/20427778/

[51] Lavine JE, Schwimmer JB, Van Natta ML, et al. "Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial." JAMA. 2011;305:1659-68. PMID: 21521847. https://pubmed.ncbi.nlm.nih.gov/21521847/

[52] Alkhouri N, et al. "The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD): a randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD)." Aliment Pharmacol Ther. 2024. PMID: 39001559. https://pubmed.ncbi.nlm.nih.gov/39001559/

[53] Pervez MA, et al. "Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized double-blind active-controlled trial." Complement Ther Med. 2022. PMID: 35933083. https://pubmed.ncbi.nlm.nih.gov/35933083/

[55] Fahn S. "The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness." Ann N Y Acad Sci. 1989;570:186-96. PMID: 2698103. https://pubmed.ncbi.nlm.nih.gov/2698103/

[56] Parkinson Study Group. "Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease." N Engl J Med. 1993;328:176-83. PMID: 8417384. https://pubmed.ncbi.nlm.nih.gov/8417384/

[57] Rajanandh MG, Kosey S, Prathiksha G. "Assessment of antioxidant supplementation on the neuropathic pain score and quality of life in diabetic neuropathy patients: a randomized controlled study." Pharmacol Rep. 2014;66(1):44-8. PMID: 24905305. https://pubmed.ncbi.nlm.nih.gov/24905305/

[58] Hor CP, Fung WY, Ang HA, et al. "Efficacy of Oral Mixed Tocotrienols in Diabetic Peripheral Neuropathy: A Randomized Clinical Trial." JAMA Neurol. 2018;75(4):444-452. PMID: 29379943. https://pubmed.ncbi.nlm.nih.gov/29379943/

[59] Kumari A, et al. "Effectiveness of Evening Primrose and Vitamin E for Cyclical Mastalgia: A Prospective Study." Cureus. 2024. PMID: 38752050. https://pubmed.ncbi.nlm.nih.gov/38752050/

[60] Pruthi S, Wahner-Roedler DL, Torkelson CJ, et al. "Vitamin E and evening primrose oil for management of cyclical mastalgia: a randomized pilot study." Altern Med Rev. 2010;15(1):59-67. PMID: 20359269. https://pubmed.ncbi.nlm.nih.gov/20359269/

[62] Dreher F, Gabard B, Schwindt DA, Maibach HI. "Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: a human study in vivo." Br J Dermatol. 1998;139(2):332-9. PMID: 9767255. https://pubmed.ncbi.nlm.nih.gov/9767255/

[63] Werninghaus K, Meydani M, Bhawan J, Margolis R, Blumberg JB, Gilchrest BA. "Evaluation of the photoprotective effect of oral vitamin E supplementation." Arch Dermatol. 1994;130(10):1257-61. PMID: 7944506. https://pubmed.ncbi.nlm.nih.gov/7944506/

[64] Mitsuishi T, Shimoda T, Mitsui Y, Kuriyama Y, Kawana S. "The effects of topical application of phytonadione, retinol and vitamins C and E on infraorbital dark circles and wrinkles of the lower eyelids." J Cosmet Dermatol. 2004;3(2):73-5. PMID: 17147559. https://pubmed.ncbi.nlm.nih.gov/17147559/

[67] Keen MA, Hassan I. "Vitamin E in dermatology." Indian Dermatol Online J. 2016;7(4):311-315. PMID: 27559512. https://pubmed.ncbi.nlm.nih.gov/27559512/

[68] Baumann LS, Spencer J. "The effects of topical vitamin E on the cosmetic appearance of scars." Dermatol Surg. 1999;25(4):311-5. PMID: 10417589. https://pubmed.ncbi.nlm.nih.gov/10417589/

[69] Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality." Ann Intern Med. 2005;142:37-46. https://pubmed.ncbi.nlm.nih.gov/15537682/

[70] Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. "Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis." JAMA. 2007;297:842-57. https://pubmed.ncbi.nlm.nih.gov/17327526/

[73] Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB. "Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?" J Natl Cancer Inst. 2008;100:773-83. https://pubmed.ncbi.nlm.nih.gov/18505970/

[75] U.S. Department of Agriculture, FoodData Central. https://fdc.nal.usda.gov/

[76] O'Connor EA, et al. "Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." JAMA. 2022. PMID: 35727272. https://pubmed.ncbi.nlm.nih.gov/35727272/

Back to blog